



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.
 • Tel. : +91-22-6121 4100 • Fax : +91-22-67031658
 Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra
 & Factory : • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912
 • E-mail : info@kilitch.com • Website : www.kilitch.com

28 February, 2012

Scrip Code : 524500
 Bombay Stock Exchange of India Ltd,
 (Corporate Relations Department),
 Floor 25, P.J. Towers,
 Dalal Street,
 Mumbai - 400 001.

Scrip Code : KILITCH
 National Stock Exchange of India Limited,
 (Listing Department),
 Exchange Plaza,
 Bandra - Kurla Complex,
 Bandra (East),
 Mumbai - 4000 051.

Sub: Completion of sale of the Business (as defined below) of Kilitch Drugs (India) Limited to Akorn, Inc through its wholly owned Indian subsidiary, Akorn India Private Limited.

Dear Sirs,

1. We refer to our communication dated October 6, 2011 informing that Kilitch Drugs (India) Limited ("Company") has entered into a Business Transfer Agreement ("BTA") with Akorn Inc., through its wholly owned Indian subsidiary, Akorn India Private Limited (together referred to as "Akorn") for sale of its business which includes research, development, manufacturing, marketing, importing and exporting of generic pharmaceutical formulation products inter-alia out of two factory units of the Company situated at Village Nihalgarh, Tehsil Paonta Sahib, Himachal Pradesh ("Business") to Akorn. As set out in our communication dated October 6, 2011, the Company has also entered into a Product Transfer Agreement *inter-alia* with Akorn ("Mumbai Product Transfer Agreement") for transferring of its business of manufacturing certain hormonal and cephalosporin pharmaceutical formulations at the Company's Navi Mumbai facility situated at C-301/2, TTC Industrial Area, MIDC, Pawane, Navi Mumbai - 400 705 ("Mumbai Business").
2. The shareholders of the Company had by postal ballot approved the sale of Business and Mumbai Business with the requisite majority on November 16, 2011.
3. We hereby inform you that the aforesaid transaction of sale of Company's Business alongwith the Mumbai Business has closed and completed today in accordance with the terms of the BTA and the Mumbai Product Transfer Agreement and the Company has received an aggregate consideration of Rs. 2,216,080,240 for the same.
4. The Company shall continue to carry on and expand the business of sales, marketing and distribution of eye care products, manufacturing from its Navi Mumbai facility and export of generic formulation products to certain overseas markets. The Company has entered into certain agreements with Akorn for manufacture of products on contract manufacturing basis for Akorn.
5. The Company has also executed a Management Services and Transition Support Agreement with Akorn whereunder the Company will provide certain transition and management services to Akorn for an additional consideration of Rs. 32.50 lacs to facilitate transition of the Business from the Company to Akorn.

Thanking you,

Yours faithfully,

For Kilitch Drugs (India) Limited

Managing Director

